Establishing an immune correlate of protection for Nipah virus in nonhuman primates DOI Creative Commons
Victor H. Leyva-Grado,

Dominique Promeneur,

Krystle N. Agans

et al.

npj Vaccines, Journal Year: 2024, Volume and Issue: 9(1)

Published: Dec. 19, 2024

The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and potential transmission from human to make NiV a concerning threat with pandemic potential. There are no licensed vaccines prevent disease. A recombinant Hendra soluble G glycoprotein vaccine (HeV-sG-V) candidate was recently tested Phase I clinical trial. Because sporadic, few cases, licensing will likely require an alternate regulatory pathway. Therefore, determining reliable correlate protection (CoP) be critical. We assessed immune responses elicited by HeV-sG-V African Green monkeys relationship challenge. Data revealed values specific binding neutralizing antibody titers that predicted survival allowed us establish mechanistic CoP for Bangladesh Malaysia strains.

Language: Английский

Nipah Virus: A Zoonotic Threat Re-Emerging in the Wake of Global Public Health Challenges DOI Creative Commons
Francesco Branda, Giancarlo Ceccarelli, Marta Giovanetti

et al.

Microorganisms, Journal Year: 2025, Volume and Issue: 13(1), P. 124 - 124

Published: Jan. 9, 2025

The re-emergence of the Nipah virus (NiV) in Kerala, India, following tragic death a 14-year-old boy, underscores persistent threat posed by zoonotic pathogens and highlights growing global public health challenge. With no vaccine or curative treatment available, fatality rates as high 94% past outbreaks, is critical concern for authorities worldwide. Transmitted primarily through contact with fruit bats consumption contaminated food, well direct human-to-human transmission, NiV remains highly lethal unpredictable pathogen. World Health Organization has classified priority pathogen due to its alarming potential cause widespread outbreaks even trigger next pandemic. Recent India Bangladesh, occurring seasonal regularity, have once again exposed vulnerability systems containing this virus. This study explores epidemiology, ecological factors driving response NiV, emphasizing role spillovers pandemic preparedness. As community grapples an increasing number emerging infectious diseases, stands stark reminder importance coordinated surveillance, rapid containment measures, urgent development novel strategies mitigate impact re-emerging threat.

Language: Английский

Citations

2
Cross-protectivity of henipavirus soluble glycoprotein in an in vivo model of Nipah virus disease DOI Creative Commons
Stephen Findlay‐Wilson, Nazia Thakur,

Lin Crossley

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 26, 2025

Nipah virus (NiV) is one of a group highly pathogenic viruses classified within the Henipavirus genus. Since 2012 at least 11 new henipa-like have been identified, including from locations and reservoir hosts; pathogenicity these has yet to be determined, but two them associated with morbidity, fatalities. The efficacy cross-reactivity vaccine candidates derived soluble glycoproteins both NiV Hendra (HeV) was evaluated in our recently established hamster model. Both preparations resulted strong humoral responses against antigenic targets, demonstrating cross-reactive immunity. Efficacy determined through challenge hamsters Malaysian (NiV-M) strain. 100% survived lethal dose after prime/boost immunisation HeV presence adjuvant, clinical signs pathology being significantly reduced immunised animals. This first time compared NiV-M model Alhydrogel AddaVax, providing evidence that closely related henipavirus species can provide cross-protectivity infection alternate henipaviruses, supporting potential an effective pan-henipavirus for use frontline outbreak response.

Language: Английский

Citations

1
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control DOI Creative Commons
Shen Wang, Wujian Li,

Zhenshan Wang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Sept. 11, 2024

Language: Английский

Citations

8
Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery DOI Creative Commons
Md. Anamul Haque, Archana Shrestha, Constantinos M. Mikelis

et al.

International Journal of Pharmaceutics X, Journal Year: 2024, Volume and Issue: 8, P. 100283 - 100283

Published: Sept. 10, 2024

Language: Английский

Citations

6
Risk of Nipah Virus Seroprevalence in Healthcare Workers: A Systematic Review with Meta-Analysis DOI Creative Commons
Matteo Riccò, Antonio Cascio, Claudio Costantino

et al.

Viruses, Journal Year: 2025, Volume and Issue: 17(1), P. 81 - 81

Published: Jan. 9, 2025

Nipah virus (NiV) is a zoonotic pathogen with the potential to cause human outbreaks high case fatality ratio. In this systematic review and meta-analysis, available evidence on NiV infections occurring in healthcare workers (HCWs) was collected critically appraised. According PRISMA statement, four medical databases (PubMed, CINAHL, EMBASE, Scopus) preprint repository medRixv were inquired through specifically designed searching strategy. A total of 2593 entries identified; them, 16 studies included qualitative quantitative analysis detailing outcome infection HCWs estimates seroprevalence among professions. All reported data from Asian countries: Malaysia, Singapore, Bangladesh, India (States Kerala Bengal), Philippines. Seroprevalence estimated seven 0.00% (95%CI 0.00 0.10) for IgM-class antibodies 0.08% 0.72) IgG class-antibodies, but sampled did not report any seropositive cases. ratio 73.52% 34.01 99.74) calculated 10 studies. conclusion, present study shows that may result possible occupational involved managing incident As most occur limited resources settings, it reasonable even basic preventive measures (i.e., mandatory use PPE appropriate isolation cases physical distancing) be quite effective avoiding occurrence new HCWs.

Language: Английский

Citations

0
Potent Cross‐neutralizing Antibodies Reveal Vulnerabilities of Henipavirus Fusion Glycoprotein DOI Creative Commons
Yi Ren, Pengfei Fan, Xinghai Zhang

et al.

Advanced Science, Journal Year: 2025, Volume and Issue: unknown

Published: April 29, 2025

Abstract Hendra and Nipah viruses (HNVs), zoonotic paramyxoviruses with >50% case fatality rates, cause fatal encephalitis respiratory disease, yet lack approved therapies. Here, nine rhesus‐derived monoclonal antibodies (mAbs) targeting the fusion glycoprotein (F) prefusion conformation are developed. Four mAbs exhibit first‐rate cross‐neutralization against HNVs, two showing synergistic potency when combined attachment (G)‐specific mAbs. Single‐dose administration of confers robust protection lethal virus challenge in hamsters. Structural insights reveal that 8 9 potent adopt a human IGHV4‐59‐like framework protruding CDRH3 loops, forming pushpin‐shaped paratopes stabilize F‐trimer by occupying vulnerable interprotomer cavities. Systematic mutational profiling identifies 14 prefusion‐locking residues within F ectodomain, classified as i) structural linchpins governing fusogenicity or ii) immunodominant hotspots targeted cross‐neutralizing This work delivers promising therapeutic candidates HNVs provides blueprints for rational design vaccines viral machinery.

Language: Английский

Citations

0
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases DOI Creative Commons
Rossella Brandi, Alessia Paganelli, Raffaele D’Amelio

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(12), P. 1418 - 1418

Published: Dec. 16, 2024

mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy adapt should antigen vary, able induce humoral cellular immunity. Methods: To date, only two COVID-19 one RSV have been approved. However, several currently under development for prevention human viral (influenza, immunodeficiency virus [HIV], Epstein–Barr virus, cytomegalovirus, Zika, respiratory syncytial metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster herpes simplex 1 2), bacterial (tuberculosis), parasitic (malaria) diseases. Results: RNA viruses, such as severe acute syndrome coronavirus (SARS-CoV)-2, HIV, influenza, characterized by high variability, thus creating need rapidly circulating strain, task that can easily accomplish; however, speed variability may be higher than time needed vaccine adapted. vaccines, using lipid nanoparticles delivery system, act adjuvants, powerfully stimulating innate well adaptive immunity, both humoral, which is waning, cell-mediated, highly persistent. Safety profiles were satisfactory, considering slight increase prognostically favorable anaphylactic reactions young females myopericarditis males has observed. Conclusions: The pandemic determined shift use RNA: after having used medicine micro-RNAs tumor new era anti-infectious begun, great development, either improve already available, but unsatisfactory, or develop protective against infectious agents no preventative tools realized yet.

Language: Английский

Citations

1
Henipaviruses: epidemiology, ecology, disease, and the development of vaccines and therapeutics DOI
Jessica R. Spengler, Michael K. Lo, Stephen R. Welch

et al.

Clinical Microbiology Reviews, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 23, 2024

SUMMARY Henipaviruses were first identified 30 years ago and have since been associated with over outbreaks of disease in humans. Highly pathogenic henipaviruses include Hendra virus (HeV) Nipah (NiV), classified as biosafety level 4 pathogens. In addition, NiV has listed a priority pathogen by the World Health Organization (WHO), Coalition for Epidemic Preparedness Innovations (CEPI), UK Vaccines Research Development Network (UKVN). Here, we re-examine epidemiological, ecological, clinical, pathobiological studies HeV to provide comprehensive guide current knowledge application identify evaluate countermeasures. We also discuss therapeutic vaccine development efforts. Furthermore, case identification, prevention, treatment mind, highlight limitations research recognize gaps necessitating additional studies.

Language: Английский

Citations

1
A Comprehensive Review of Nipah Virus: From Epidemics to Approaches of Management DOI Creative Commons
Himanshu Pandey, Pallavi Pandey, Vikash Jakhmola

et al.

Journal of Pure and Applied Microbiology, Journal Year: 2024, Volume and Issue: 18(3), P. 1502 - 1514

Published: Aug. 23, 2024

Nipah virus (NiV) continues to remain a significant threat health of the public, characterized by its ability cause respiratory and neurological complications. The World Health Organization (WHO) has identified NiV as priority disease for R D Blueprint. However, despite extensive research efforts, specific antiviral therapies infection are currently unavailable. This highlights crucial need focus on supportive care patients affected NiV. Therapies Prompt medical attention, including mechanical ventilation intensive care, is in case infection. Preventive measures such avoiding consumption raw date palm sap implementing control practices, gives major role halting spread review provides comprehensive overview NiV, unique characteristics, clinical manifestations, diagnostic methods, treatment strategies, preventive measures. article also details vaccines undergoing trials, ChAdOx1, PHV02, mRNA-1215, HeV-sG-V, CD40.NiV. In addition, it that m102.4 monoclonal antibody nucleotide analogue remdesivir shown effective Non-Human Primate (NHP) model was reviewed.

Language: Английский

Citations

0
Modeling the benefits of virus discovery and pandemic virus identification DOI Creative Commons

Geetha Jeyapragasan,

Jakob Graabak,

Stephen P. Luby

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 27, 2024

Abstract Preventing and mitigating future zoonotic pandemics are global health priorities, but there few quantitative estimates of how best to target interventions. Here we construct a mathematical model evaluate the benefits 1) virus discovery sequencing (VDS) in animals 2) pandemic identification (PVI) via laboratory characterization potential. Drawing on historical data expert surveys One Health vaccine researchers, estimate that intensifying efforts by three-fold could prevent between 0 1.46 million expected deaths per decade improving non-pharmaceutical interventions broad-spectrum vaccines. In contrast, because researchers well over hundred pandemic-capable viruses nature, through would 48,000 [10,500; 93,600], or just ∼0.62% deaths. Further identifications offer diminishing returns. Given wide-ranging survey responses limited cost-effectiveness compared proven such as insecticide-treated bed nets, our suggests establishments aiming mitigate should focus monitoring spillover hotspots empowering local communities detect, sequence, suppress nascent epidemics rather than characterizing potential laboratories.

Language: Английский

Citations

0